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INTRODUCTION 
Swine breeding goals are directed toward producing the 
maximum amount of lean red meat per unit of feed, time and 
labor. In seeking this goal, animals have been selected for 
growth rate, muscling and a lack of fat. Selection has 
been reasonably successful as evidenced by the observed 
changes in growth rate and carcass composition. These 
readily observable changes must correspond to physiologic 
changes within the animal. These physiologic changes are 
not readily observable and have not been extensively investi­
gated. 
The physiologic changes are of interest to population 
geneticists because they may be highly correlated with 
economically important traits. If so, they could be used to 
estimate genetic potentials for traits which cannot be 
evaluated unless animals are sacrificed, and to decrease the 
error in estimates of genetic potential for lowly heritable 
and for sex-limited traits. 
Many types of physiologic traits could be correlated 
with readily observable phenotypes. Circulating growth 
hormone level is a physiologic trait that is probably re­
lated to rate of gain, protein deposition and fat catabolism. 
An immunoassay sensitive enough to measure circulating levels 
of growth hormone is being used in many species. 
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The purpose of this research was to develop an immuno­
assay to measure circulating levels of porcine growth hormone 
and to investigate the relationships of circulating hormone 
level to growth rate and carcass composition in genetically 
diverse groups of swine. The experiment was designed so 
that it afforded an opportunity to investigate the accuracy 
of the assay as well as the relationship of hormone level to 
the age of the pigs. 
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REVIEW OF LITERATURE 
The literature review is divided into four main sections. 
Section I is concerned with the relationship between growth 
hormone and carcass composition. The research in this area 
is of two main classes. The first class involves treatment 
of intact and hypophysectomized animals with exogenous growth 
hormone. The second class involves attempting to measure 
the amount of growth hormone available and correlating this 
measure with growth and carcass composition. 
Section II includes investigations into growth hormone 
action which brings about the observed variations in growth 
rate and carcass composition. 
Section III contains literature related to growth hormone 
action at the cellular level. This section deals mainly 
with the effect of growth hormone upon amino acid transport 
and protein synthesis. 
Section IV is concerned with the theory of immunoassay, 
the technique used to measure circulating levels of growth 
hormone. 
Section I: Relationship of Growth Hormone 
to Growth Rate and Carcass Composition 
Bierring and Nielson (1932) found that rats treated 
with an alkaline pituitary extract gained weight faster than 
control animals not receiving pituitary extract. The 
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carcasses of the treated rats contained higher percentages 
of protein and water and less fat. Lee and Schaffer (1934) 
reported that rats treated with bovine anterior pituitary 
extract gained faster and increased body length faster than 
controls. The treated rat carcasses contained more total 
nitrogen, water and ash with less total fat. The treated 
and control rats were pair-fed so that the differences were 
not due to differential feed consumption. 
Young (1945) reported that pituitary extract treatment 
of rats, dogs and cats led to faster weight gains and in­
creased nitrogen retention. The carcasses of treated rats 
contained less fat and more protein and water than their 
pair-fed controls. Evans, Simpson and Li (1948) treated 
210-day old female rats with growth hormone for 437 days. 
The treated rats increased body length and live weight 
faster than the controls. The average weight gain for the 
437 day period was 289 grams for the treated rats while that 
for the controls was 59 grams. Li, Simpson and Evans (1948) 
found that growth hormone treated rats fed ^  libitum had 
carcasses containing less fat and more water and protein 
than untreated control rats. 
Samuels, Reinecke and Baumann (1943) demonstrated that 
force-fed hypophysectomized rats deposited less protein 
nitrogen and more fat than did intact controls. Turman and 
Andrews (1955) treated seven barrows with growth hormone and 
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maintained seven as controls. The treated barrows did not 
gain significantly faster than the controls. The control 
animals required significantly more feed per 100 pounds of 
gain (384 pounds vs. 310 pounds). The carcasses of the 
growth hormone treated barrows contained more water and 
The treated barrows had significantly 
the average live animal backfat probe 
of the treated barrows was 0.37 inches less than that for 
the controls. 
Li and Evans (1948) demonstrated that the reduced growth 
rate of hypophysectomized rats can be partially corrected by 
treatment with growth hormone. 
Baird, Nalbandov and Norton (1952) , utilizing 86 pigs, 
investigated the pituitary growth hormone content of two 
lines of pigs selected for fast and slow gain. The growth 
hormone content of the pituitaries was determined by the 
tibia test in young hypophysectomized rats. The pituitary 
growth hormone content of the fast growing line was signifi­
cantly higher than that of the slow growing line at all 
weights and at all ages above 56 days. The difference between 
lines in anterior pituitary potency was almost constant at 
all ages. The total anterior pituitary growth hormone content 
of the fast growing line increased from 56 days to 115 days 
and dropped significantly at 154 days of age. In the slow 
growing line the total pituitary growth hormone content 
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increased from 56 days to 75 days and dropped at 154 days 
of age. 
• Baker, Jr. et al. (1956) investigated the relationship 
of total pituitary growth hormone to age and mature size in 
pigs. They found that the total pituitary potency per unit 
body weight declines from birth to 225 days of age and main­
tains the 225 day level thereafter. Baird et al. (1952) 
also reported that the amount of pituitary growth hormone 
per unit body weight decreases with age. Armstrong and 
Hansel (1956) investigated the relationship of pituitary 
growth hormone content to plane of nutrition and age in 
Holstein heifers. They observed six animals in each age 
by nutrition level subclass. The pituitary growth hormone 
content per unit live weight decreased with age. They 
reported a correlation of 0.37 between growth hormone per 
unit pituitary mass and the percent increase in body weight 
during the 16 weeks prior to slaughter. The correlation 
between pituitary growth hormone per 100 pounds live weight 
and the percent increase in body weight during the 16 weeks 
prior to slaughter was 0.65. The correlation between the 
percent increase in wither height in the last 16 weeks prior 
to slaughter and growth hormone per unit pituitary weight was 
0.42 while the correlation of pituitary growth hormone per 
100 pounds live weight with the percent increase in wither 
height was 0.54. The level of nutrition had no significant 
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effect upon growth hormone per unit pituitary weight or 
growth hormone per 100 pounds live weight. 
The literature cited in this section suggests that 
growth hormone influences the following; 
a) protein deposition and water retention; 
b) fat deposit or the mobilization and catabolism of 
fat; 
c) weight gain and skeletal growth. 
Section II: Growth Hormone and Protein 
(amino acid) Conservation 
Greenbaum (1953) studied the effect of level of feed 
consumption and growth hormone treatment upon rats. He had 
three treatment groups; 1) controls, 2) fed ad libitum and 
received growth hormone, and 3) limited food intake and 
received growth hormone. After 70 days the group 1 rats had 
increased their protein content by 25%, the group 2 rats had 
increased their protein content by 86%, and the group 3 rats 
had increased their protein content by 57%. The control 
(group 1) rats maintained a constant percent fat over the 
70 days. The group 2 rats at first lost fat and then in­
creased it slowly until at the end of the 70-day experiment 
they contained 70 percent as much as did the controls. The 
group 3 rats lost fat and contained only one-half as much as 
the controls at the end of the 70-day experiment. The period 
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of fat loss in the treated rats corresponds to a period during 
which the animals exhibited a lowered respiratory quotient, 
indicating that a larger than normal portion of their energy 
was being derived from fat catabolism. 
Knobil (1959) demonstrated that adipose tissue from 
growth hormone treated hypophysectomized rats released 
significantly more non-esterified fatty acids ^  vitro than 
does adipose tissue from saline injected hypophysectomized 
rats. Knobil and Creep (1959) reported that glucose and 
food abolished the increased plasma non-esterified fatty 
acid response to growth hormone treatment in the monkey. 
They also demonstrated that the fat mobilizing effect of the 
growth hormone was not due to contamination by thyroid 
stimulating hormone, leuteothrophin or adrenocorticotrophic 
hormone. Neither TSH or LTH caused fat mobilization. ACTH 
caused fat mobilization but did not reduce insulin sensitivity 
or glucose tolerance as did the growth hormone treatment. 
Goodman and Knobil (1959) found that hypophysectomized monkeys 
exhibit elevated plasma levels of non-esterified fatty acids 
upon fasting. The elevation was much less in hypophysectomized 
than in intact monkeys. In the simian growth hormone treated 
hypophysectomized monkey the non-esterified fatty acid rise 
in response to fasting was of the same magnitude as the fatty 
acid rise seen in normal intact monkeys after fasting. 
Barrett et (1938) reported that growth hormone treatment 
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induced a rapid increase in the rate of transfer of peripheral 
fat depots to the liver and depressed the respiratory 
quotient. Greenbaum and McLean (1953) found that growth 
hormone treatment resulted in an increased rate of lipid 
mobilization to the liver. Goodman and Knobil (1951) 
demonstrated that removal of the pituitary gland, the adrenal 
gland, or the thyroid gland reduced the degree of non-
esterified fatty acid rise in response to fasting. These 
authors concluded that the pituitary, adrenal, and thyroid 
glands are necessary for the fatty acid response to fasting 
but they do not initiate the response. 
Dole (1956) found that fasted individuals exhibit 
elevated plasma levels of non-esterified fatty acids. He 
also reported that oral glucose, a meal, or injected insulin 
depressed the non-esterified fatty acid rise during fasting. 
Winkler et (1964) demonstrated that growth hormone treated 
dogs exhibit elevated plasma non-esterified fatty acids. In 
addition they noted that the rate of fatty acid oxidation is 
dependent upon the rate of uptake which in turn is dependent 
upon the plasma levels. Through this chain of events growth 
hormone does indirectly effect the rate of fatty acid oxidation. 
Raben and Hollenberg (1959) found that the non-esterified 
fatty acid rise during fasting could be abolished by food 
consumption, oral glucose plus insulin, and insulin alone. 
They also reported elevated plasma non-esterified fatty acids 
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in response to growth hormone treatment. This occurred in 
both normal and diabetic dogs. Normal human subjects exhi­
bited elevated plasma non-esterified fatty acids when treated 
with human or simian growth hormone. 
Roth et al. (1963) reported that hypoglycemia induced 
by either exercise or insulin would result in raised plasma 
levels of growth hormone. No growth hormone rise was observed 
after exercise or hypoglycermia if the animals were pre-
treated with glucose. Administration of 2-deoxy-D-glucose, 
which inhibits intracellular glucose utilization, results in 
hyperglycemia with hypoglycemic symptoms within the cell. 
Treatment with 2-deoxy-D-glucose resulted in elevated plasma 
levels of growth hormone. This suggests that glucose utiliza­
tion at the intracellular level is important in eliciting 
the elevated growth hormone levels observed in times of 
energy shortage. 
Hunter et (1965) reports that exercise elicits a 
rise in plasma levels of growth hormone and non-esterified 
fatty acids while lowering plasma levels of glucose. The 
respiratory quotient is also reduced during exercise. In­
gestion of glucose during exercise tended to nullify the rise 
in plasma levels of growth hormone and non-esterified fatty 
acids while the respiratory quotient remained normal. 
These results agree with the findings of Roth et (1963) 
and suggest that, if energy is readily available, the plasma 
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growth hormone level is not elevated during periods of great 
energy utilization. 
From the literature reviewed in Section II one can 
safely conclude that growth hormone has an effect upon the 
rate of fatty acid mobilization and fat catabolism. During 
periods when glucose is not available in adequate quantities 
to supply the energy needs of the animal, plasma levels of 
growth hormone and fatty acids are raised. As indicated 
by the lowered respiratory quotient, fatty acids are used as 
an energy source. If the fatty acid levels were not raised 
in response to reduced available glucose, energy needs 
would be met through protein and amino acid utilization. 
The fat mobilizing effect of growth hormone can be referred 
to as a protein and amino acid conserving effect. 
Section III: Growth Hormone and Amino Acid 
Transport and Protein Synthesis 
The increased rate of weight gain observed in growth 
hormone treated animals is accompanied by increased nitrogen 
retention. (Li and Evans 1948, Smith et 1955) 
Increased nitrogen retention could result from increased 
protein synthesis and/or decreased amino acid and protein 
catabolism. Li and Evans (1948) demonstrated that growth 
hormone administered to hypophysectomized rats caused an in-
32 
creased rate of P uptake. This indicates that the rate of 
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nucleic acid synthesis was increased, an expected happening 
if the increased nitrogen retention were the result of 
increased protein synthesis. 
Korner (1959, 1961) demonstrated, using a cell-free 
system, that hypophysectomy depressed the ability of 
ribosomes to assemble amino acids into polypeptide chains. 
The same author in 1965 demonstrated that growth hormone 
administered after actinomycin treatment resulted in increased 
protein synthesis. Actinomycin blocks ribonucleic acid 
synthesis. Therefore the increased protein synthesis re­
sulting from growth hormone treatment is not completely due 
to increased ribonucleic acid synthesis. Korner (1965) 
suggests that growth hormone may cause polyribosome formation 
from single ribosomes, thus providing more ribonucleic acid 
"readers" and increased protein synthesis. 
Kostyo and Schmidt (1962a, 1962b) demonstrated that 
growth hormone treatment will induce amino acid accumulation 
within the cells of a muscle vitro. The same authors 
(1962a) found that prolactin was the only other pituitary 
hormone tested which caused increased intracellular accumu­
lation of an amino acid. The effect of growth hormone on 
intracellular amino acid accumulation in vitro was shown to 
be independent of insulin. Kostyo and Engel (1960) found 
that adrenocorticotrophic hormone did not stimulate intra­
cellular amino acid accumulation ^  vitro. Riggs and Walker 
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(1960) found that amino acid accumulation in rat muscle cells 
was reduced by hypophysectomy. They also demonstrated that 
treatment with growth hormone returned the level of intra­
cellular amino acid accumulation to normal in hypophysecto-
mized rats. 
Noall et ad. (1957) demonstrated that growth hormone 
treatment of adult female rats elicited an increased accumu­
lation of intracellular labelled amino acids. Knobil and 
Roth (1963) found that growth hormone did not cause intra­
cellular accumulation of valine when protein synthesis was 
blocked with puromycin. Puromycin treatment did not stop 
intracellular accumulation of the nonmetalolizable amino 
acid, alpha-amino isobutyric acid. 
It has been demonstrated that growth hormone treatment 
results in increased intracellular accumulation of amino 
acids. This effect could result from direct stimulation of 
an amino acid transport mechanism or by stimulation of 
protein synthesis which would result in more amino acid 
transport into the cell. Regardless of whether growth hormone 
affects amino acid transport directly or indirectly it does 
cause an increase in protein synthesis. 
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Section IV; Immunoassay Theory 
The principle of immunoassay can be illustrated by the 
following schematic taken from a paper by Bearson et al. 
(1964). 
labelled antibody against  ^ labelled hormone 
hormone the hormone  ^ antibody complex 
+ 
unlabelled 
hormone 
1 1  
unlabelled hormone 
antibody complex 
This system contains a constant amount of labelled hormone 
and antibody. The amount of unlabelled hormone in the system 
varies. The quantity of antibody present will bind 55 to 
65% of the labelled hormone when no unlabelled hormone is 
present. The unlabelled hormone added will compete with the 
labelled hormone for the limited quantity of antibody présent. 
Due to this competition, there is an inverse relationship 
between the amount of unlabelled hormone added and the amount 
of labelled hormone that binds to the antibody. The points 
on a standard curve are gotten by adding various amounts of 
unlabelled hormone (e.g., 0.5, 1.0, 2.0, 3.0 myg) to a 
constant amount of labelled hormone and antibody. 
Many types of standard curves are used to assay micro 
\ ! quantities of hormone in serum. We most frequently used 
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curve is constructed by plotting the B/F ratio against the 
quantity of unlabelled hormone added. Here B is equal to the 
radioactivity (counts per minute) of labelled hormone bound 
to antibody and F is equal to the radioactivity (counts per 
minute) of the labelled hormone that is free in solution. 
Figure la shows a curve of this type, a second type of 
standard curve is obtained when the B/F ratio is plotted 
against thé "logarithm of the amount of unlabelled hormone 
added (Figure lb). Herbert et (1965) used a standard 
curve constructed so that it is linear with a positive slope. 
They plotted B/B' against the quantity of unlabelled hormone 
added to the standard tubes. B equals the radioactivity 
(counts per minute) of the labelled hormone bound to antibody 
when no unlabelled hormone is added and B' is the counts per 
minute of labelled hormone bound to antibody in the standard 
tubes containing various quantities of unlabelled hormone 
(Figure Ic). The type of standard curve used in this study 
is illustrated in Figure Id. This curve is constructed by 
plotting the percentage of the total radioactivity added 
that is bound to antibody against the quantity of unlabelled 
hormone present in the tubes. 
The amount of hormone in a serum sample is estimated by 
combining a small quantity of serum (0.1 ml.) with labelled 
hormone (same amount used in standard tubes) and anti­
serum (the same quantity and dilution as in the standard 
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Figure la 
Figure Ib 
3 / F  
1 0 2 3  
B / F  
1 0 3  2 
m^tg unlabelled log n^g unlabelled 
hormone hormone 
Figure le 
1 2  3  
n y x g  u n l a b e l l e d  
h o r m o n e  
Figure Id 
w  5 0 -
1 2  3  
ny/g unlabelled 
hormone 
Figure 1. Standard curves used to assay micro quantities of 
hormone in serum 
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tubes). The hormone contained in the serum will compete 
with the labelled hormone for the limited quantity of anti­
body available. The percent of the total radioactivity 
added that is bound to the antiserum is determined. The 
percent bound is located on the ordinate of the standard 
curve and a horizontal straight line is drawn from this point 
through the standard curve. This line is the dashed line on 
Figure Id, the point of standard curve intersection is marked 
P. A second straight line, parallel to the ordinate, is 
drawn from point P through the abscissa. This is the dotted 
line on Figure Id. The point where this dotted line inter­
sects the abscissa (incremented in myg hormone) provides the 
estimate of the quantity of hormone in the unknown serum 
sample. 
The following chart illustrates the various types of 
tubes that must be made up to run as assay. 
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Tube ,1 to .2myg , Standard lOmyg/ml 
No. labelled PGH Antibody diluent^  unlabelled Serum 
PGHd 
0 lOOyl 0 400yl Oyl lOOyl 
1 lOOyl 0 500yl 0 0 
2 100]il lOOyl 400yl 0 0 
3 lOOyl lOOyl 375yl 25yl 0 
4 lOOyl lOOyl 350yl 50yl 0 
5 lOOyl lOOyl 300yl lOOyl 0 
6 lOOyl lOOyl 250yl 150yl 0 
7 lOOyl lOOyl 200yl 200yl 0 
8 lOOyl lOOyl lOOyl 300yl 0 
9 lOOyl lOOyl 0 400yl 0 
10 lOOyl lOOyl 300yl Oyl lOOyl 
11 lOOyl lOOyl 250yl 50yl lOOyl 
Chart 1. Protocol for an assay 
S^olution of labelled porcine growth hormone diluted in 
standard diluent contains one to two myg PGH per ml. 
D^iluted so that 100 lambda binds 55 to 65 percent of 
labelled hormone added. 
S^tandard diluent -.25% BSA Veronal buffer pH 8.6 (I=î1) . 
S^olution of unlabelled porcine growth hormone diluted 
in standard diluent contains 10 myg PGH per ml. 
The 0 tubes are called serum controls and the 1 tubes are 
called no antibody controls. Tubes 2 through 9 are points on 
the standard curve while tubes 10 and 11 are examples of un­
known serum tubes. 
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I 
IMMUNOASSAY PROCEDURE 
The immianoassay procedure used in this study consisted 
of a mixture of many procedures described in the literature. 
Each of the following objectives must be accomplished 
before unknown serum samples can be assayed to determine 
their growth hormone content: 
1) obtain a pure standard hormone sample; 
2) label a quantity of the standard hormone with a 
radioactive isotope; 
3) obtain an antiserum that will bind the labelled and 
unlabelled standard hormone; 
4) find a method of separating the labelled hormone 
bound to antibody from the labelled hormone not 
bound to antibody; 
5) determine what dilution of the antiserum will bind 
55 to 65 percent of the 0.1 mpg to 0.2 m^ g of 
labelled hormone added to all tubes; 
6) combine the labelled hormone, properly diluted 
antiserum and unlabelled hormone to get a standard 
curve ; 
7) run trials to determine the extent of serum damage 
to the labelled hormone. 
Objective number one was expediently achieved due to 
the generosity of Dr. A. E. Wilhelmi who kindly provided a 
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5 mg sample of porcine growth hormone. 
Greenwood et al. (1963) , Utiger et (1962) , Click 
et al. (1963), Yalow and Bearson (1960), and Hunter and 
Greenwood (1962) describe techniques for labelling proteins 
with radioactive iodine. The protein labelling procedures 
described in the publications cited above are similar to 
the procedure used in this study. 
The procedure used to label porcine growth hormone in 
this study is described below. Five micrograms of porcine 
growth hormone in five lambda of solution was combined 
with 1-1/4 millicuries of iodine-125 in 25 lambda of 0.5M 
phosphate buffer, pH 7.6. Twenty-five lambda of chloramine-T 
(35 mg/lOml) was added to the above mixture. After gently 
shaking for thirty seconds, 100 lambda of sodium-meta-bisulfite 
(24mg/10ml) was added and the mixture was allowed to stand 
four to five minutes. Then 200 lambda of potassium iodide 
(lOmg/lOml) was added and the entire mixture was transferred 
to a 25 ml sephadex G-lOO column. The mixture was eluted 
with 0.015 M veronal buffer (pH 8.6) . 
The 25 ml. sephadex column was presaturated with one 
milliliter of bovine serum albumen in veronal buffer 
(30 mg BSA/ml). This presaturation minimizes the quantity 
of labelled hormone that adsorbs to the glass column and 
sephadex beads. One milliliter elutes were collected in 
tubes containing 200 lambda of a one percent solution of 
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bovine serum albumen in veronal buffer (0.015 M, pH 8.6). 
A typical elution pattern is depicted in Figure 2a. The 
first peak consists of labelled growth hormone whose secondary 
structure has been destroyed. The second peak is the intact 
labelled growth hormone and the third peak consists of 
free iodine. 
Before the labelled hormone is used in an assay it is 
further purified by running a 100 to 200 lambda sample of 
the labelled hormone solution on a 50 ml sephadex G-lOO 
column. This column is presaturated with bovine serum al­
bumen and the elution is carried out with 0.015 M veronal 
buffer, pH 8.6, One milliliter elutes are collected in 
tubes containing 200 lambda of the one percent bovine serum 
albumen buffer. A typical elution pattern appears in Figure 
2b. 
The middle peak consists of the intact labelled growth 
hormone molecule which binds very readily with the antibody 
against growth hormone. The first peak consists of mole­
cules whose effective molecular size (rotating radius) is 
greater than that of the intact growth hormone molecule. 
This first peak contains hormone molecules whose secondary 
structure has been destroyed. The last peak contains 
molecules whose effective size is smaller than that of the 
immunologically active growth hormone molecule. This peak 
consists of fragments of growth hormone molecules. The 
Figure 2, Figures illustrating elution patterns and an 
antibody dilution trial 
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Figure 2a 
8x10 
•H 
•H 
Tube Number 
Figure 2c 
70-
Figure 2b 
30" 
2x10 
1:10000 1:10 
Antibody Dilution 
•H 
Tube Number 
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middle peak is used in the assay after it has been diluted 
so that the concentration of labelled hormone is one to 
two millimicrograms per milliliter. It is diluted in one-
quarter percent bovine serum albumen veronal buffer pH 8.6. 
This BSA buffer is referred to as standard diluent in the 
remainder of this dissertation. 
The antiserum used in this study was produced in guinea 
pigs by repeated subcutaneous injections of porcine growth 
hormone, obtained from Nutritional Biochemicals Corp., Cleve­
land, Ohio. Five milligrams were injected each time over a 
period of five months. Each animal received six injections, 
the first three with complete Freund's adjuvant and the last 
three without adjuvant. Antisera to human growth hormone 
has been produced in the rabbit but our attempts to produce an 
antiporcine growth hormone antibody in rabbits failed. 
Techniques used to produce antiserum against growth hormone 
(human) are given by Read and Bryan (1960) and by Utiger et al. 
To determine the quantity of labelled hormone bound to 
antibody, the labelled hormone not bound to antibody must be 
separated from that bound to antibody. This separation can 
be accomplished by paper electrophoresis (Bearson et al. 
1964, Yalow and Bearson 1960, and Hunter and Greenwood 1964). 
The pattern of radioactivity on the electrophoresis strip 
will vary depending on what hormone is being assayed. For 
porcine growth hormone, the free labelled hormone would be 
electrophoretically immobile and would therefore be adsorbed 
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at the origin. The porcine growth hormone bound to antibody 
would migrate toward the cathode. These electrophoresis 
strips are counted in an automatic strip counter or are cut 
into smaller pieces and each piece is counted separately in 
a conventional sodium iodide crystal scintillation detector. 
The separation of antibody bound from free labelled 
hormone can be accomplished by using a second antibody. 
(Schalch and Parker, 1964, Machlin ejb al_. 1968, Schalch and 
Reichlin 1966, and Utiger et al. 1962). This second anti­
body is produced against gamma-globulin from the species 
used to produce the antibody against the hormone. This 
second antibody will precipitate the labelled hormone-antibody 
complex leaving the labelled hormone not bound to antibody 
in solution. Herbert et (1965) used dextran coated 
charcoal to adsorb the free labelled hormone from solution, 
leaving the labelled hormone-antibody complex in the super­
natant. Norit A neutral pharmaceutical grade charcoal is 
coated with dextran 80, average molecular weight 80,000. 
The dextran coat on the charcoal acts as a molecular sieve. 
The free labelled hormone is adsorbed to the charcoal while 
the larger labelled hormone-antibody complex is not 
adsorbed since it cannot penetrate the dextran coat. 
In the present study dextran coated charcoal was used to 
separate the labelled hormone-antibody complex from the free 
labelled hormone. This technique was first applied un-
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successfully in the porcine growth hormone system because the 
dextran coated charcoal adsorbed both the labelled hormone-
antibody complex and the free labelled hormone from solution. 
When this happens there appears to be no labelled hormone 
bound to antibody, since essentially all the added radio­
activity is adsorbed to the charcoal. Adding serum (porcine, 
bovine, rabbit, guinea pig) to the tubes immediately before 
adding the dextran coated charcoal prevents the adsorption 
of the labelled hormone-antibody complex. Since the free 
labelled hormone is adsorbed, the technique is quite 
successful. 
Since quantity of serum in the tube when the dextran 
coated charcoal is added influences the adsorption of the 
free labelled hormone to charcoal, all tubes should contain 
equal amounts of serum when the dextran coated charcoal is 
added. 
Antisera dilution trials were run to determine at what 
dilution 100 lambda of the antiserum would bind 55 to 65% of 
the quantity of labelled hormone being used. Antiserum dilu­
tion tubes contain 400 lambda of standard diluent, 100 
lambda of labelled hormone (0.1 to 0.2 myg), and 100 lambda of 
antiserum at various dilutions. Duplicate no antibody control 
tubes are included. These tubes contain 0.5 ml of standard 
diluent and 100 lambda of labelled hormone. All tubes were 
incubated two days at 4°C. The tubes are shaken daily during 
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the incubation period. 
At the end of the incubation period, 100 lambda of serum 
is added to each tube. Immediately after this addition, 2 
ml of the dextran coated charcoal is added to each tube. 
The tubes are then placed in the refrigerator at 4*C. 
After 15 minutes the tubes are removed from the refrigerator 
and inverted to thoroughly mix the contents. The tubes are 
then centrifuged (lOOOg) for thirty minutes at 4°C. 
During centrifugation the dextran coated charcoal, with 
the adsorbed free labelled hormone, is packed in the bottom 
of the tube. After centrifugation the supernatant which con­
tains the labelled hormone-antibody complex is removed by 
aspiration. The tubes containing the charcoal (unbound 
labelled hormone) are counted. The counter used was a well-
type sodium-iodide crystal scintillation detector. 
The radioactivity(fcjounts per minute) of the no antibody 
control tubes is the total radioactivity available to the 
dextran coated charcoal. This total available radioactivity 
will represent 90 to 97 percent of the total radioactivity 
added to these tubes. The counts per minute of the tubes con­
taining the various antibody dilutions are expressed as per­
centages of the total available radioactivity. These percent­
ages are the percentage unbound (not bound to antibody) radio­
activity. The percent antibody bound radioactivity is ob­
tained by subtracting the percent unbound from 100 percent. 
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The antibody was tried at dilutions of 1:10, 1:100, 1:1000, 
1:2000, 1:3000, 1:4000, 1:5000 and 1:10,000. The percent 
antibody-bound radioactivity is plotted against the antibody 
dilution. This graph is shown in Figure 2c. The dilution 
of antibody used is that one at which 100 lambda of the anti­
body solution will bind 55 to 65 percent of the total avail­
able radioactivity. 
The points on a standard curve are obtained by combining 
a constant amount (0.1ml) of antibody at the proper dilution 
with different amounts of unlabelled hormone and standard 
diluent. Each tube contains a final volume of 0.5 ml. These 
tubes are incubated at 4°C for two days. During incubation 
the tubes are shaken daily. At the end of the two-day incu­
bation period, each tube receives 0.1 ml of the labelled 
growth hormone solution containing 0.1 to 0.2 m^ g of the 
labelled hormone. After this addition the tubes are incu­
bated for two more days at 4®C. They are again shaken daily. 
At the end of the fourth day of incubation all tubes receive 
0.1 ml serum and 2 ml dextran coated charcoal. The tubes 
are held at 4®C for 15 minutes and are inverted to mix the 
contents. They are centrifuged (1000 g for 30 minutes) at 
4®C and the supernatant is aspirated. 
The tubes containing the charcoal are counted and the 
count is expressed as a percentage of the total radioactivity 
available. The total radioactivity available is determined 
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by running no antibody control tubes, just as in the antibody 
dilution trial. The percent antibody-bound radioactivity is 
calculated. The percent antibody-bound radioactivity is 
plotted against the amount of unlabelled hormone added to 
the various standard curve tubes. See Figure Id for an 
example standard curve. 
The amount of growth hormone in a particular serum sample 
is estimated by replacing the unlabelled hormone of the 
standard tube with the serum being assayed. These tubes con­
tain labelled hormone, antibody, serum, and enough standard 
diluent to make a final volume of 0.5 ml. The antibody, 
serum, and standard diluent are incubated for two days. 
The labelled hormone is added and the tubes are incubated 
for two more days. Separation of antibody-bound radio­
activity from free radioactivity is accomplished by using 
dextran coated charcoal. 
The only real difference between a standard curve tube 
and a tube containing a serum sample is the presence of the 
serum. The samples are treated exactly alike until the end 
of incubation. At this time 0.1 ml serum is added to all 
standard curve tubes, bringing their total volume to 0.7 
ml. The serum limknown tubes receive 0.1 ml. of standard 
diluent, bringing their final volume to 0.7 ml. Therefore, 
when 2 ml, of dextran coated charcoal is added, all tubes 
contain equal quantities of serum and the same final volume. 
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The percent antibody-bound radioactivity is determined for 
the tubes containing the serum samples being assayed. 
Tubes which do not contain antibody but do contain 
labelled hormone and serum during incubation are called 
serum control tubes. They are expected to have the same 
percent unbound radioactivity as the no antibody control 
tubes. This expectation is not realized, because the amount 
of labelled hormone (radioactivity) available to the dextran 
coated charcoal is reduced by the presence of serum during 
incubation. This reduction in available radioactivity is 
called "serum damage" and must be corrected for when esti­
mating the percent unbound radioactivity for the serum 
sample under assay. 
The presence of 100 lambda of serum during incubation 
will reduce the amount of radioactivity adsorbed to the 
charcoal by 4 to 12 percent and 200 lambda will cause a 
reduction of 10 to 20 percent. This problem seems to be 
particularly acute when dealing with porcine growth hormone. 
The various publications dealing with immunoassay of hormones 
in other species give very little attention to the problem 
of serum damage. Other authors treat serum damage as a 
constant effect common to all serum samples assayed and they 
correct their observations accordingly or not at all. 
The usual serum correction procedure is to run serum 
control tubes. These tubes contain serum and standard diluent 
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for the first two days of incubation and they also contain 
0.1 ml of labelled hormone during the last two days. The 
charcoal adsorbed radioactivity of the serum control tubes 
is lower than the charcoal adsorbed radioactivity in the no 
antibody control tubes. This difference is expressed in 
counts per minute and designated "serum damage." The correc­
tion for serum damage can be made by simply adding the serum 
damage counts per minute to the observed charcoal adsorbed 
counts per minute for each serum sample assayed. A propor­
tional correction can be made. In this case the average 
charcoal adsorbed radioactivity of the serum control tubes 
is divided by the charcoal adsorbed radioactivity in the no 
antibody control tubes. This correction factor (K<1) is 
used to correct the charcoal adsorbed radioactivity of the 
tubes containing the serum samples being assayed. 
The proportional correction method assumes that the 
following relationship holds. 
(cpm observed with serum present) = K(cpm observed without 
serum) 
This implies that the serum damages a constant proportion 
of the labelled hormone not bound to antibody, resulting in 
its not adsorbing to dextran coated charcoal. The correction 
will be less for tubes which exhibit low counts per minute on 
the charcoal (low level of unlabelled hormone) and more for 
those having higher counts per minute on the charcoal (higher 
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level of unlabelled hormone). Therefore, the charcoal 
adsorbed radioactivity of serum samples containing large 
amounts of growth hormone receive large corrections while 
serum samples with low levels of hormone receive low correc­
tions. The additive method of correction assumes that all 
tubes, regardless of \inlabelled growth hormone content, 
receive the same amount of serum damage. An attempt was made 
to determine which serum damage correction was best. This 
was done by running three "standard curves". Set #1 was a 
typical standard curve, set #2 was a series of standard 
curve tubes each of which received 50 lambda of hypophysecto-
mized pig serum and set #3 was a series of standard curve 
tubes each of which received 100 lambda of norm^ al pig serum. 
The percent antibody bound radioactivity was calculated and 
the conventional standard curve was plotted using the set 
#1 tubes. The quantity of unlabelled growth hormone in each 
of the set #2 and set #3 tubes was estimated using this con­
ventional standard curve. These estimates were then corrected 
for serum damage using the two proposed correction methods. 
The resulting estimates of growth hormone level appear in 
the body of Tablé 1. The assay indicated that the hypo-
physectomized pig serum contained no growth hormone. Serum 
damage (lowered charcoal adsorbed activity) was evident in 
normal serum and hypophysectomized serum. This is apparent 
since at every hormone level the growth hormone content of 
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Table 1. Indicated growth hormone levels using two methods 
of serum damage correction 
Amount of PGH added to the tube 
1/2 my g 1 my g 1-1/2 
myg 
2 myg 3 myg 
No Set #2 0 my g .9 my g 1.4 myg 1.85 myg 2.25 myg 
serum * 
correction Set #3 0 .9 1.83 2.52 
Proportional Set #2 .5 1 .0 1.5 2.0 2.47 
serum * 
correction Set #3 .68 1 .13 2.25 3.08 
Additive Set #2 .75 1 .08 1.53 2.05 2.7 
serum 
* 
correction Set #3 .97 1 .44 2.55 3.5 
* 
Indicates no value at this level of unlabelled hormone. 
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the tubes of set #2 and #3 was underestimated if no correction 
was made for serum damage. The amount of underestimation 
was less in the set #3 tubes. This is understandable since 
the normal serum probably contained growth homone. 
With one exception the proportional correction procedure 
raised the estimated growth hormone content of the set #2 
tubes to the level expected if there had been no growth 
hormone in the hypophysectomized serum. The exception 
occurred in the tube containing 3 myg of hormone. Here the 
proportional correction was not large enough, resulting in 
an underestimate of the hormone content. The proportional 
serum damage correction of the tubes in set #3 gave estimates 
of hormone content greater than the amount of hormone added. 
This is reasonable since the normal serum probably contained 
growth hormone in addition to that added. 
In the set #2 tubes the additive correction procedure 
overestimated the amount of growth hormone present at every 
level except the highest (3 myg added). This overestimation 
was greatest in the tube containing 1/2 mpg of hormone. The 
amount of hormone estimated in the tubes of set #3 was greater 
than the amount added at every level of addition. 
These results suggest that the proportional correction 
would be best at the lower levels of hormone while the additive 
correction is superior at higher levels of hormone. These 
results also suggest that the degree of serum damage depends 
34 
upon the level of unlabelled hormone present. If this is 
true and different serum samples contain different levels 
of hormone, it follows that different serums will cause 
different amounts of serum damage. 
The solution adopted for this study was to have at least 
one serum control tube for each serum sample assayed and to 
use the additive correction for serum damage. 
Preliminary observation of many standard curves revealed 
that variation between the standard curves is to be expected. 
The most frequently observed inconsistency was the large 
variation in the slope of the curve between zero and one-
half myg of unlabelled hormone. Preliminary study also 
led the author to suspect that a high proportion of the 
0.1 ml serum samples assayed would contain less than 1/2 
myg of hormone. This level of hormone would correspond 
to the most inconsistent portion of the standard curve. 
Therefore, one-half myg of unlabelled hormone was added to 
each tube containing 0.1 ml of serum being assayed. One-
half myg of hormone was also added to each serum damage 
control tube so that it would, with the exception of anti­
body, have the same contents as the unknown serum tubes. 
The amount of hormone present in a serum sample was found by 
subtracting one-half myg from the level indicated by the 
assay. 
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SOURCE OF DATA AND EXPERIMENTAL DESIGN 
The eighty gilts used in this study were chosen from 
parents which differed widely in rate of gain. This was done 
in order to have a wide range of growth rates within the 
experimental group. Only gilts were used in order to avoid 
differences that might exist between sexes in the traits 
measured. 
The pigs were fed ^  libitum and provided about 200 
square feet of pen space per pig. The pigs were provided 
shelter and shade in the dirt lots. Twenty to thirty 
pigs were housed in each of the three lots. The pigs were 
born and housed for the whole experiment on the swine 
breeding farm at Napier. 
Each pig was weighed at birth and again at weaning, 
at about 56 days of age. Each litter, selected to partici­
pate in this experiment was placed in one of the lots when 
weaned. The pigs were weighed each week so that their weight 
the following week could be predicted reasonably well. Blood 
samples were taken at weaning when the pigs weighed 25 to 40 
pounds, when they weighed 100 pounds and when they weighed 
200 pounds. All pigs were slaughtered at 200 pounds. Carcass 
information consisting of body length, backfat, loin eye area 
and ham and loin percentage was obtained. 
Research indicates that in other species the plasma 
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level of growth hormone is greatly elevated in response to 
stress. Therefore it was thought necessary to minimize the 
amount of stress experienced by the pigs just prior to 
bleeding. To minimize stress, the pigs were not weighed 
until after they had been bled and they were bled as quickly 
as possible with a minimum of handling. The blood samples 
were obtained by slashing a vein on the back of the ear. 
Preliminary trials indicated that this technique afforded 
the best opportunity to quickly obtain a small (1/2 to 1 ml) 
blood sample. 
When the blood samples were being collected it was 
thought that 0.3 ml of serum would be enough to permit making 
duplicate determinations of growth hormone level. However, 
preliminary results indicated that serum damage would differ 
from one serum sample to another. In an effort to test this 
preliminary observation and to control serum damage, at 
least one serum damage control tube was run for each serum 
sample assayed. Where possible, duplicate serum damage 
control tubes and duplicate hormone level determinations were 
made on each serum sample. When serum samples were not large 
enough to permit this, duplicate hormone level determinations 
were run with one serum damage control. A few serum samples 
were so small that only one hormone level determination and 
one serum damage control could be run. The assay procedure 
was such that 30 serum samples could be analyzed in one 
37 
operation (assay). Therefore eight assays were conducted. 
Ten pigs were randomly assigned to each of the eight assays. 
The following chart illustrates the experimental 
design, 
: è3i 
Pig Weaning 100 lbs, 200 lbs, 
1,1 XX^  00^  XX 00 XX 00 
Assay 1 
1,10 XX 00 XX 00 XX 00 
8,1 XX 00 XX 00 XX 00 
Assay 8 , , , . . 
8,10 XX OO XX 00 XX 00 
Chart 2, Experimental design 
X^X represents two serum damage determinations. 
0^0 represents two hormone level determinations. 
The hormone level determinations were expressed in myg 
of hormone per milliliter of serum. The serum damage values 
were expressed as the percent reduction in charcoal adsorbed 
radioactivity in the serum control tubes. 
The following model illustrates the statistically 
controllable sources of variation affecting an observed 
growth hormone level or serum damage value. 
i^jkl = ; + + Pij + ^ ijk i^jkl 
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Where: 
i^jkl ~ observed hormone level (myg/ml) or an 
observed serum damage value (percent serum 
damage) 
U = mean hormone.level or serum damage value common 
to all Y's 
(i=l,...,8) = effect common to all observations 
., . th in the 1 assay 
P\j(i=l,...,10) = effect common to all observations 
on the pig within the i^  ^assay 
Ti^ (^k=l,2,3) = effect common to all observations 1JK 
on the k^  ^age or time when the 
sample on the pig within i^  ^assay 
dijki(l=lf2) = a random error associated with the 
1^  ^observed value for hormone level 
or serum damage in the k^  ^blood 
sample from the j pig within the 
. th 1 assay 
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Table 2a. Assay means for serum damage and growth hormone 
Assay 
1 2 3 4 5 6 7 8 
Mean hormone 
level 
6.36 1.65 4.79 2.83 3.74 2.29 2.69 5.23 
Mean serum 
damage 
5.97 4.98 5.67 4.53 4.32 6.18 3.08 4.13 
Table 2b. The AOV of serum damage values 
Source df Mean sq. Component Percentage 
Assays 7 50.34* .86 12.57 
Pigs/A 72 10.01* .89 12.97 
Ages/P/A 148 5.72* 1.06 15.47 
Dete rminations 144 4.05 4.05 58.99 
* 
Significant at the ,001 level. 
Table 2c. The AOV of growth hormone levels 
Source ' df — Mean sq. Component Percentage 
Assays 7 135.36* . 2.33 22.81 
Pigs/A 72 13.69 .18 1.81 
Ages/P/A 148 12.28* 5.70 55.94 
Determinations 190 1.98 1.98 19.45 
* 
Significant at the .001 level. 
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RESULTS AND DISCUSSION 
Serum Damage 
The total variation of the serum damage values was 
partitioned into four sources. The analysis of variance ap­
pears in Table 2b on page 39. The sources of variation are 
(1) differences between assays, (2) differences between 
pigs within assays, (3) differences between serum samples 
collected from the same pig at three different ages, and 
(4) differences between determinations made on the same 
serum sample. All mean squares are highly significant. In 
this analysis the experimental unit is the serum sample. 
Determinations mean square 
The determinations mean square represents the difference 
between duplicate determinations made on the same serum 
sample. This mean square estimates the true random experi­
mental error and is used to test the mean square for ages. 
The two major sources of error that contribute to differences 
between duplicate serum damage values are counting errors and 
errors in laboratory technique. 
Errors in laboratory technique cause the contents of 
duplicate serum damage control tubes to differ in total 
volume and composition. The total volume that a tube con­
tains when the dextran coated charcoal is added influences 
the adsorption of labelled hormone to the charcoal. There-
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- fore variation in total volume causes differences between 
duplicate serum damage determinations. 
The composition of the contents of a tube influences 
the adsorption of labelled hormone to the dextran coated 
charcoal. Serum damage control tubes contain standard 
diluent, serum, and labelled hormone. Variation in labelled 
hormone content influences the amount of labelled hormone 
that adsorbs to the dextran coated charcoal. The amount of 
labelled hormone that adsorbs to the dextran coated charcoal 
is influenced by the quantity of serum present. This effect 
of serum upon the charcoal adsorption of labelled hormone was 
described earlier. 
Errors in counting the charcoal adsorbed radioactivity 
contribute to the variation between duplicate serum damage 
determinations. The counting error associated with a particu­
lar count is a function of .the length of the count and the 
total number of counts detected. If a total count, C, is 
observed over a period of time, t minutes, the mean and 
variance of the total count is C. Therefore the standard 
deviation of a counting rate, R=C/t, is given by 
The counting error can be reduced by increasing the time of 
the count. 
In this study, all tubes were counted five minutes. 
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The counts ran from 6,000 to 13,000, This means that the 
standard deviations of the counting rates range from 23 to 
15 counts per minute. 
The mean square for ages within pigs 
This mean square contains a component attributable 
to random error and a component which reflects differences 
between serum samples taken from the same pig at three 
different ages. The mean square for differences between 
ages is significant. This indicates that serum samples 
taken from the same pig at different times (ages) cause 
significantly different amounts of serum damage. 
Many serum characteristics probably change as the pig 
becomes older. Any of these changes could cause significant 
differences between serum damage values for samples taken from 
the same pig at different ages. One readily observable 
serum characteristic that may contribute to the age component 
in the analysis of serum damage values is the degree of 
hemolysis. This possibility should be investigated in sub­
sequent studies. 
The mean square for pigs within assays 
This mean square contains a random error component, a 
component for ages within pigs, and a component for pigs 
within assays. The mean square for pigs within assays is 
significant when tested against the ages mean square. This 
test measures the significance of the component attributable. 
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to pigs, since the expected mean squares for ages and pigs 
differ only by the pig component. The significant F value 
indicates that serum samples from different pigs cause 
significantly different amounts of serum damage. Serum 
characteristics that differ from pig to pig with consistency 
over the three ages are responsible for the significant mean 
square for pigs. The nature of these characteristics is 
not known. 
The mean square for assays 
The assay mean square, tested against the mean square 
for pigs, proved to be highly significant. This indicates 
that the degree of serum damage differs significantly from 
one assay to the next. The mean serum damage values for the 
eight assays are presented in Table 2a on page 39. 
The assay component will be influenced by assay 
characteristics which vary from assay to assay but are common 
to all observations within an assay. The amount and age of 
the labelled growth hormone used will vary from assay to 
assay and will influence the observed serum damage values. 
Growth Hormone Level 
The total variation of the growth hormone determinations 
was partitioned into the same four sources as was the serum 
damage determinations. The analysis of variance is given in 
Table 2c on page 39. The determinations mean square is the 
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measure of the true experimental error and is estimated by 
the difference between duplicate determinations made on the 
same serum sample. The square root of this mean square esti­
mates the standard deviation (a= 1.407 myg) of a growth 
hormone determinations. 
The determinations mean square 
This mean square is influenced by two sources of error. 
The errors associated with counting radioactivity contribute 
to the differences between duplicate determinations. The 
nature and extent of the counting error was discussed 
earlier. Errors resulting from laboratory technique contribute 
to the observed determinations mean square. Errors in 
laboratory technique cause duplicates to differ in total 
content and composition of the contents. 
Variations in total volume of the contents influence 
the reaction between antibody and antigen. The total volume 
when dextran coated charcoal is added influences the adsorp­
tion of labelled hormone to the charcoal. 
Variation between duplicates in serum content contributes 
to the determinations mean square in two ways. First, the 
serum content during incubation affects the antigen-antibody 
reaction because the serum contains growth hormone which is 
the antigen. Secondly, the serum content influences the ad­
sorption of labelled hormone to the dextran coated charcoal. 
Duplicate tubes may receive different amounts of labelled 
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and iinlabelled growth hormone. The quantity of hormone 
(labelled or unlabelled) present during incubation influences 
the antigen-antibody reaction and therefore contributes to 
the observed difference between duplicate tiibes. Variation 
in the quantity of antibody added affects the antigen-antibody 
reaction and thus cause differences between duplicates. 
Errors in serum damage determinations contribute to the 
error involved in estimating the growth hormone content of a 
serum sample. The errors between serum damage determinations 
on the same serum sample do not contribute to the variation 
between growth hormone determinations made on the same serum 
sample. This is true because the average of the two serum 
damage determinations is used as a correction factor for both 
of the growth hormone determinations made on the same serum 
sample. 
The mean square for ages 
Changes with time in the hormone content of a pig's 
serum are reflected in the age component. The age component 
is influenced by any factor which changes from one bleeding 
to the next. Factors which do not change with time affect 
the age component if the pig's reaction to these factors 
changes with time. The degree of stress to which a pig is 
subjected at bleeding varies with time and the pig's reaction 
to a constant amount of stress may change with time. Both of 
these factors contribute to the age component. 
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The amount of stress is probably one of the largest 
sources of extraneous variation influencing the observed 
growth hormone level. An attempt was made to minimize the 
effect of stress by collecting the blood samples quickly and 
with a minimum of handling. If blood samples are collected 
in the same way at every age, this should help make the 
effect of stress constant for all ages. 
The mean square for age is significant, indicating that 
the change in growth hormone level with age is too great to 
have occurred by chance. The mean hormone level at weaning 
was 5.41 myg/ml. The standard deviation of this estimate was 
0.486 mpg. The mean weaning weight was 37.8 pounds. The 
mean hormone level at 100 pounds was 3.33 myg/ml with a stan­
dard of 0.273 mug/ml. The average age of pigs at this bleed­
ing (100 pounds) was 110.3 days and the average pig weighed 
113.5 pounds at this age. The mean hormone level at the 
third bleeding (200 pounds) was 2.82 myg/ml with a standard 
deviation of 0.204 myg. The average age and weight of pigs 
at the third bleeding were 174 days and 203.7 pounds, 
respectively. 
The circulating growth hormone level decreases with age. 
This agrees with the results of Machlin et al. (1968). Baker 
Jr. et (1956) and Baird et al. (1952) reported that 
pituitary growth hormone content per unit body weight 
decreased with age. Relating the results of Baird and Baker 
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to those of Machlin and myself, we see that both the circu­
lating hormone level and the pituitary hormone content per 
unit body weight decreases with age. This does not suggest 
a positive relationship between circulating hormone level 
and pituitary hormone content per unit body weight at a given 
age. 
The mean square for pigs within assays 
This mean square is not significant, indicating that the 
differences between pigs in growth hormone level averaged 
across ages could easily be due to chance variation. The 
pig component could be inflated by any factor which did not 
change with time but did differ from one pig to the next. 
For example, different pigs react differently to stress and 
this reaction may not change with time. ..If this is the case, 
the reaction to stress could contribute to the pig component 
without influencing the age component. 
The mean square for assays 
The mean square for assays is significantly larger than 
the mean square for pigs within assays. The significant 
difference between assays could scarcely be due to sampling 
variation in the assignment of pigs to assays, because the 
pigs were randomly assigned to assays. The mean hormone 
levels for the eight assays are given in Table 2a on page 39, 
The significant assay mean square results from the 
large assay component. This component is influenced by 
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assay characteristics which vary from assay to assay but 
are constant within an assay. The amount and age of the 
labelled growth hormone used varies from one assay to the 
next and influences the observed growth hormone level. 
There are errors in antibody dilution and errors in making 
up the standard growth hormone solution. These errors 
contribute to the assay component but do not contribute to 
the other components because only one dilution of antibody 
and one dilution of standard hormone was made per assay. 
Correlations of Growth Hormone Levels with 
Growth Rate and Carcass Traits 
Growth hormone is a complex chemical produced by the 
anterior pituitary. Research into the nature of its action 
indicates that its functions are many and quite complicated. 
Growth hormone has a positive effect upon growth rate and 
protein deposition in many species. It has also been impli­
cated as a regulator of fat deposition and catabolism. 
Research dealing with hypophysectomy and growth hormone 
replacement therapy emphasizes the vital role played by 
growth hormone in the physiological well-being of an animal. 
In spite of the voluminous writings on growth hormone, 
very little is actually known about it. The correlations 
presented and discussed on the next few pages are based upon 
a small number of observations and the errors associated with 
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these observations are admittedly quite large. Therefore, 
the following discussion should be regarded as a collection 
of ideas which may or may not contain truths. 
The correlations presented in Table 3 on page 50 were 
calculated by pooling the within-assay product moment 
correlations. Therefore, these correlations are not in­
fluenced by differences between assays. The correlations 
among the growth hormone levels at the three ages are. about 
what one would expect. The positive (0.20) correlation of 
hormone level at weaning with hormone level at 100 pounds is 
not significant but does exceed the correlation between 
weaning hormone level and the hormone level at 200 pounds. 
The (0.36) correlation between the hormone level at 100 pounds 
and that at 200 pounds is significant. The hormone level at 
each age is positively and significantly correlated with 
hormone level averaged over ages. This is to be expected, 
since the average level is calculated as the mean of the 
three determinations. 
The work of Baird et a^ . (1952) shows a positive relation­
ship between growth rate and growth hormone content of the 
anterior pituitary. The relationship between plasma hormone 
level and pituitary hormone content is not known. By some 
mechanism, possibly feedback, the release of hormone from the 
pituitary is regulated so that the circulating level is kept 
relatively constant for pigs of a particular age. The 
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Table 3. Correlations of growth hormone levels with rate of 
gain and carcass traits&rb 
Weaning 100# 200# 
GH level GH level GH level 
Growth hormone at 100 pounds 
O
 
CM +
 
Growth hormone at 200 pounds -.07 + .36 
Average of 3 GH levels 
o
 
00 +
 + .74 +. 41 
21-Day weight + .26 -.02 -.10 
Weaning weight + 0 -.03 -.16 
Carcass length -.04 -.03 -.18 
Loin Eye Area -.20 -.12 
00 o
 
+
 
Ham and Loin % -.03 -.12 -.21 
Carcass Backfat -.13 - 0 + .23 
ADG (Birth-weaning) - 0 -.05 -.18 
ADG (Weaning-100#) -.36 - 0 + .05 
ADG (100#-200#) -.26 -.14 — .20 
ADG (Weaning-200#) -.35 -.09 -.07 
T^o be significant at the 5% level r^ .27. 
T^o be significant at the 1% level r^ . 36. 
analysis of variance of hormone levels indicated that there 
was no significant difference between pigs in average plasma 
growth hormone level. If this is the case, the rate of 
hormone turnover or the rate of hormone release from the 
pituitary would be positively correlated with growth rate. 
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In this system the circulating hormone level would probably 
be negatively correlated with growth rate. This would occur 
because faster-growing animals would remove the hormone from 
the blood faster and their circulating hormone level would 
be near the lower boundary of the range in hormone level 
normal for pigs of that age. The slower growing animals would 
exhibit hormone levels near the upper boundary of the range 
in hormone level. 
The observed correlations between circulating hormone 
levels and measures of growth rate are negative with one 
notable exception. The exception is the 0.26 correlation 
between hormone level at weaning and the 21-day weight. 
This correlation is not significant but suggests that the 
plasma hormone level is positively related to rate of growth 
when both are observed in young animals. 
The correlations between hormone levels and rate of 
growth in later life are negative. This suggests that the 
faster-growing animals exhibit lower plasma hormone levels. 
This observation supports the idea that faster-growing animals 
remove the hormone from circulation faster and therefore 
exhibit lower circulating hormone levels. 
The observed correlations between circulating hormone 
levels and the carcass traits are all nonsignificant. The 
weight gained by a pig is due to an increase in total mass. 
This mass consists mostly of muscle, fat and bone. The 
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proportion of the total increase in mass that is attributable 
to each of these three components differs with the age of the 
animal. In the early growth stages (from birth to about 150 
pounds) the increase in weight is due largely to an increase 
in muscle. This period is one of rapid protein deposition 
and during this time the ratio of protein deposition to fat 
deposition is high. As the animal becomes older this ratio 
decreases. In mature animals most of the weight change is 
attributable to changes in the fat content of the body. 
The circulating growth hormone levels at weaning and 
100 pounds are negatively correlated with loin eye area. 
The hormone levels at all three ages are negatively correlated 
with the percentage ham and loin. Both loin eye area and 
percentage ham and loin are positively associated with carcass 
protein content and negatively correlated with carcass fat 
content. Carcass length is negatively correlated with 
circulating growth hormone level at all three ages. Many 
authors have reported that growth hormone has a positive 
influence upon protein deposition and bone growth. If those 
animals which are utilizing growth hormone at the faster 
rates are the animals which exhibit lower plasma hormone 
levels, the above negative correlations agree with the accepted 
positive relationship of growth hormone to protein deposition 
and bone growth. 
The correlations between carcass backfat and the 
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circulating hormone level at weaning, 100 pounds and 
200 pounds are -.13, 0, and 0.23 respectively. During the 
later (after 150 pounds) growth stages the amount of fat 
deposition is increasing. It is the plasma hormone level 
observed during this time which shows a positive correlation 
with carcass backfat. This suggests that those animals 
having a high plasma hormone level at 200 pounds also yield 
carcasses with high backfat thickness. If the plasma hormone 
level is negatively related to the rate of hormone utilization, 
these observed correlations support the idea that growth 
hormone has a positive effect on fat catabolism and there­
fore a negative effect upon fat content. 
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CONCLUSIONS 
The first objective of this work was to develop an 
immunoassay to measure circulating levels of growth hormone 
in the pig. This objective has been achieved. 
Finding that different serum samples cause significantly 
different amounts of damage to the labelled growth hormone 
is an important result. This result suggests that careful 
control and correction for serum damage is of great importance 
and should possibly be given more attention in subsequent 
work. One might also wonder about this in other species. 
This study supports the conclusions of Machlin et al. 
(1968) regarding the decline in circulating growth hormone 
level with age. The results of this work strongly suggest 
that a negative relationship exists between the circulating 
growth hormone level and the rate of growth hormone utili­
zation. This point could be investigated further by doing 
a rate of utilization or rate of turnover study using labelled 
growth hormone. The relationship of the rate of utilization 
with growth rate, carcass traits and circulating hormone 
levels could provide conclusive evidence about the postulated 
negative relationship between rate of hormone utilization 
and circulating hormone level. 
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